Source comparison
Selank Amidate vs Thymosin Alpha-1: Research Application Comparison
Primary Mechanism GABA-A receptor modulation; HPA axis normalization TLR-9 and TLR-2 agonism; dendritic cell activation Entirely distinct pathways. Central vs peripheral Immune Effect Type Indirect (via stress reduction) Direct (receptor-mediated immune activa
This comparison does not assign a generated winner or score.
- Primary Mechanism
- GABA-A receptor modulation; HPA axis normalization
- TLR-9 and TLR-2 agonism; dendritic cell activation
- Entirely distinct pathways. Central vs peripheral
- Immune Effect Type
- Indirect (via stress reduction)
- Direct (receptor-mediated immune activation)
- Selank prevents suppression; TA-1 activates baseline function
- Typical Dosing (research)
- 0.15–0.3 mg/day intranasal or subcutaneous
- 1.6 mg subcutaneous twice weekly
- Dosing frequency reflects half-life differences
- Half-Life
- ~20 minutes (plasma); effects persist 6–12 hours
- 2–3 hours (plasma)
- Selank's duration exceeds plasma presence due to receptor changes
- Primary Research Focus
- Anxiety, cognitive performance, stress resilience
- Viral immunity, cancer, sepsis, vaccine adjuvants
- Rarely studied in the same protocol
- Observed Immune Markers
- Normalized lymphocyte counts, reduced IL-6/TNF-alpha under stress
- Elevated IFN-alpha, IL-12, CD8+ T-cell counts
- Marker profiles confirm distinct mechanisms